<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916431</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-6231-P101</org_study_id>
    <nct_id>NCT04916431</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults</brief_title>
  <official_title>A Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Administration of mRNA-6231, Encoding for a Human Serum Albumin - Interleukin-2 Mutein Fusion Protein (HSA-IL2m), in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to evaluate the safety and tolerability of escalating doses of&#xD;
      a single subcutaneous (SC) administration of mRNA-6231.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose levels of mRNA-6231 are planned to be investigated in a dose-escalation manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious AEs</measure>
    <time_frame>Up to Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of mRNA (Serum) and SM-86 (Plasma)</measure>
    <time_frame>Predose (1 hour prior to study drug administration), 0.5, 1, 2, 4, 6, and 8 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) of mRNA (Serum) and SM-86 (Plasma)</measure>
    <time_frame>Predose (1 hour prior to study drug administration), 0.5, 1, 2, 4, 6, and 8 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum to Observed Effect (TEmax) after a Single Administration of mRNA-6231</measure>
    <time_frame>Predose (1 hour prior to study drug administration), 0.5, 1, 2, 4, 6, and 8 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Effect (Emax) after a Single Administration of mRNA-6231</measure>
    <time_frame>Predose (1 hour prior to study drug administration), 0.5, 1, 2, 4, 6, and 8 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Effect Versus Time Curve (AUEClast) after a Single Administration of mRNA-6231</measure>
    <time_frame>Predose (1 hour prior to study drug administration), 0.5, 1, 2, 4, 6, and 8 hours postdose on Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 4 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 4 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 5 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 5 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 6 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 6 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 7 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 7 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 8 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 dose of Dose Level 8 of mRNA-6231 by subcutaneous injection on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mRNA-6231</intervention_name>
    <description>Sterile frozen liquid dispersion for injection</description>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 1</arm_group_label>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 2</arm_group_label>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 3</arm_group_label>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 4</arm_group_label>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 5</arm_group_label>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 6</arm_group_label>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 7</arm_group_label>
    <arm_group_label>Expansion Group - mRNA-6231 Dose Level 8</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 1</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 2</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 3</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 4</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 5</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 6</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 7</arm_group_label>
    <arm_group_label>Sentinel Group - mRNA-6231 Dose Level 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Understand and agree to comply with the study procedures and provide written informed&#xD;
             consent&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has received any investigational product (for example, study drug, biologic, device)&#xD;
             within 30 days or 5 elimination half-lives, whichever is longer&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Men and women of childbearing potential without effective contraception during the&#xD;
             study&#xD;
&#xD;
          -  Has any lab abnormalities or clinically significant medical condition that could&#xD;
             interfere with the interpretation of study results or limit the participant's&#xD;
             enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network Limited</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-6231</keyword>
  <keyword>Messenger RNA</keyword>
  <keyword>Moderna</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

